Inventiva announces further progress achieved in the clinical development of lanifibranor for the treatment of NASH 21 February 2019
Inventiva Announces Results From Phase IIb Clinical Trial with Lanifibranor in Systemic Sclerosis 18 February 2019
New results on lanifibranor to be presented at the International Liver Congress™ 2019 4 February 2019
Inventiva Announces Two Poster Presentations at the American College of Rheumatology Conference 10 October 2018
Inventiva advances in the development of lanifibranor with the achievement of three key milestones 30 August 2018
Inventiva’s lanifibranor found to have good safety profile following first assessment of carcinogenicity studies’ results 13 August 2018
Inventiva Announces Positive DSMB Reviews in both NASH and Systemic Sclerosis Phase IIb Trials with Lanifibranor 10 July 2018
Inventiva Announces a U.S. Phase II Investigator-Initiated Study with Lanifibranor on Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes 3 April 2018
Lanifibranor carcinogenicity studies: Progressing as planned and interim results in rats indicate no compound related urinary bladder tumors 28 March 2018
Inventiva’s paper on the discovery and synthesis of its panPPAR agonist lanifibranor accepted and published in the Journal of Medicinal Chemistry of the American Chemical Society 13 March 2018
Inventiva Announces Positive DSMB Review in Phase IIb FASST Trial in Systemic Sclerosis with Lanifibranor 4 January 2018
Inventiva’s Phase IIb FASST Trial in Systemic Sclerosis with Lanifibranor Completes Enrollment 17 October 2017
